Suven Life Sciences

'Suven alone has multiple engines of growth across all segments and a strong pipeline of Phase 3 and late Phase 2 molecules'

CLOSING BELL: The S&P BSE Sensex ended with a marginal loss of 88 points, while the Nifty held the 18,300-level on Friday.

Stocks to watch today: Tata Motors bagged order for 1,000 buses from Haryana Roadways; ABFRL inked pact with Galeries Lafayette to open luxury department stores in India

Clinical trial randomisation is the process of assigning patients by chance to groups that receive different treatments

The stock had hit a 52-week low of Rs 62 on June 20, 2022, and has corrected 50 per cent from its record high level of Rs 124 touched on October 8, 2021

Stocks to Watch Today: Indiabulls Housing Finance and RBL Bank are the two stocks in F&O ban period on Tuesday.

Markets regulator Sebi on Thursday disposed of proceedings against Suven Life Sciences Ltd, Jasti Family Trust and four other individuals, including the firm's chairman and CEO Venkateshwarlu Jasti

Healthcare companies to post decent growth in revenues in Q3FY21

As part of the study, Suven tested the drug as a unique triple combination with Aricept (donepezil) and Namenda (memantine) on 564 patients in the US for at least one year

The company has completed a 'stalking horse agreement' as mandated by a bankruptcy court to buy the assets of Rising Pharmaceuticals, Suven Life Sciences said in a regulatory filing

This potential acquisition of Rising's assets would transform Shore Suven Pharma into a strong US generic pharmaceutical company

These patents are valid through 2036, the company said in a BSE filing

The stock hit a 52-week high of Rs 338, rallied 88% in past four months, trading close to its record high of Rs 339 touched on April 15, 2015 on the BSE.

The NCE will be useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Huntington's disease, Parkinson's and schizophrenia

These patents are valid through 2031, 2034, 2034 and 2036 respectively, the company said in a BSE filing

The stock moved higher by 6% to Rs 192 on the BSE in noon deal after the company's Pashamylaram's unit successfully completed the USFDA inspection

The patents are valid till 2032, 2030 and 2034, respectively, the company said in a BSE filing

BS ReporterHyderabad, 17 August: Hyderabad-based bio pharmaceutical company Suven Life Sciences has received process patents for its new chemical entities(NCE) from Europe, Japan and New Zealand. These process patents are for a pipeline of compounds being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with Neurodegenerative disorders such as Alzheimer's, Attention Deficiency Syndrome(ADHD) among other diseases, according to the company."We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,"said Venkat Jasti, CEO of Suven.Suven has 4 clinical stage compounds, one phase 2 undergoing, one phase 2 ready and one phase 1 completed and one phase 1 commenced molecules. In addition to these clinical compounds, the company has nine internally discovered therapeutic drug candidates ...

Last year, in the same quarter, it reported a profit of Rs 25.24 crore

The patents are for new chemical entities used in the treatment of Alzheimer's and Schizophrenia